Does Abilify Cause Abnormal Uterine Bleeding?
No, aripiprazole (Abilify) is not documented to cause abnormal uterine bleeding based on FDA labeling and available clinical evidence.
Evidence from FDA Drug Labeling
The official FDA prescribing information for Abilify does not list abnormal uterine bleeding or menstrual irregularities as adverse reactions 1. The comprehensive adverse reaction profile includes:
- Common side effects (≥5% incidence): akathisia, restlessness, insomnia, constipation, fatigue, somnolence, extrapyramidal symptoms, nausea, and blurred vision
- Serious warnings: increased mortality in elderly with dementia, suicidal thoughts, metabolic changes, orthostatic hypotension, leukopenia, and compulsive behaviors
- Pregnancy-related effects: extrapyramidal symptoms in neonates and potential effects on milk supply during lactation
Notably absent from this extensive list is any mention of uterine bleeding or menstrual disorders.
Clinical Context
The guidelines on abnormal uterine bleeding classify causes using the PALM-COEIN system 2:
- Structural causes: polyps, adenomyosis, leiomyoma, malignancy
- Non-structural causes: coagulopathy, ovulatory dysfunction, endometrial disorders, iatrogenic (medications), and other causes
While medications can cause AUB through the "iatrogenic" category, this typically involves:
- Hormonal contraceptives
- Anticoagulants (which significantly increase AUB risk, particularly rivaroxaban 3)
- Gonadotropin-releasing hormone agents
Antipsychotics like aripiprazole are not recognized as iatrogenic causes of AUB in clinical guidelines.
Mechanism Considerations
Aripiprazole works as a partial dopamine agonist and does not directly affect:
- Coagulation pathways
- Endometrial structure
- Hormonal regulation of the menstrual cycle in ways that would cause bleeding
The research on aripiprazole in pregnancy 4 noted complications like hypertension and lower birth weight, but did not identify uterine bleeding as a concern.
Clinical Recommendation
If a patient on Abilify presents with abnormal uterine bleeding, investigate other causes systematically rather than attributing it to the medication. Evaluate for:
- Structural lesions via transvaginal ultrasound 5
- Coagulopathies (particularly if on anticoagulants)
- Ovulatory dysfunction
- Thyroid disease and prolactin levels 2
- Endometrial pathology in at-risk patients
Do not discontinue aripiprazole based solely on concurrent AUB without identifying an alternative cause, as this represents correlation without established causation and may destabilize the underlying psychiatric condition.